Therefore, also in prostate tumors the biochemical intermediates involved in NF-κB activation and augmented IL-6/CCL5 gene expression might represent adequate therapeutic targets aiming at interfering with one or more of the MAPKs activation pathway(s), thereby counteracting their effects on tumor cell proliferation and migration. Here, IL6 is linked to neoplasm.